XKRX
078160
Market cap279mUSD
Oct 08, Last price
9,590.00KRW
1D
-4.00%
1Q
3.79%
Jan 2017
-82.34%
IPO
-85.58%
Name
Medipost Co Ltd
Chart & performance
P/E
—
P/S
5.09
EPS
—
Div yield, %
—
Shrs. gr., 5y
17.33%
Rev. gr., 5y
8.66%
Revenues
73.66b
+4.25%
Net income
-85.40b
L+36.58%
CFO
-57.15b
L+53.34%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Medipost Co., Ltd. is a biotechnology firm dedicated to the creation and manufacturing of stem cell-based products. Its diverse operations are categorized into several divisions: the Cord Blood Bank, which specializes in the collection and storage of newborn umbilical cord stem cells; Stem Cell Therapy, focused on producing allogeneic stem cell pharmaceuticals; Health Functional Food, offering various vitamins and nutritional supplements; and the Import and Distribution of Natural Cosmetics division, responsible for the sales and marketing of natural cosmetic products sourced from Pevonia Inc. Additionally, the company provides comprehensive Healthcare Services, encompassing bizcare, insu-care, affiliate programs, telehealth, and medical devices, accessible via web, mobile, and call centers. Established on June 26, 2000, by Yoon-Sun Yang and Won-Il Oh, Medipost Co., Ltd. is headquartered in Seongnam, South Korea.
Key people
Dong Jin Hwang
President · since 2022
Won Yil Oh
Chief Executive Officer, Director · since 2022
Jang Won Lee
Vice President, Director · since 2012
Su Jin Choi
Managing Director
Hye Gyeong Hong
Managing Director
Mi Hyeon Jung
Assistant Managing Director
Seung Jin Lee
Assistant Managing Director
Se Mi Nam
Assistant Managing Director
Hyeok Jun Nam
Assistant Managing Director
Sang Je Sung
Assistant Managing Director
Tae Ho Yang
Assistant Managing Director
Byeong Su Jung
Non-Executive Director · since 2022
Jin Heon Kim
Other Non-Executive Director · since 2013
Yeong Min Kim
Other Non-Executive Director · since 2022
Gi Du Lee
Other Non-Executive Director · since 2022
Non-Executive Independent Director · since 2022
Je Won Lee
Non-Executive Independent Director · since 2022
Hyeon Gi Min
Non-Executive Independent Director · since 2012
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||